A D1 receptor antagonist, ecopipam, for treatment of tics in tourette syndrome

Clinical Neuropharmacology

Volumn 37, Issue 1, 2014, Pages 26-30

  Gilbert, Donald L ^a   Budman, Cathy L ^b   Singer, Harvey S ^c   Kurlan, Roger ^d   Chipkin, Richard E ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Northwell Health   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OVERLOOK HOSPITAL   (United States)

^e Ruxton Pharmaceuticals   (United States)

Author keywords

clinical trial; D1 receptor; dopamine; ecopipam; Tourette syndrome

Indexed keywords

ADOLESCENT; ADULT; BENZAZEPINES; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TICS; TOURETTE SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895073920     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000017     Document Type: Article

References (48)

1. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010;25:1538-1549.
2. Mink JW. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Adv Neurol 2006;99:89-98.
3. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381. (Pubitemid 16055790)
4. Gurney K, Prescott TJ, Redgrave P. A computational model of action selection in the basal ganglia. I. A new functional anatomy. Biol Cybern 2001;84:401-410. (Pubitemid 33605190)
5. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005;4:149-159. (Pubitemid 40269145)
6. Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002;159:1329-1336. (Pubitemid 34832714)
7. Gilbert DL, Christian BT, Gelfand MJ, et al. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 2006;67:1695-1697. (Pubitemid 44747951)
8. Mink JW. Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatr Neurol 2001;25:190-198. (Pubitemid 32913134)
9. Baym CL, Corbett BA, Wright SB, et al. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain 2008;131:165-179.
10. Chapel JL, Brown N, Jenkins RL. Tourette's disease: symptomatic relief with haloperidol. Am J Psychiatry 1964;121:608-610.
11. Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009:CD006996 John Wiley & Sons Ltd.
12. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60:1130-1135. (Pubitemid 36418773)
13. Andersen PH. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 1988;146:113-120. (Pubitemid 18030430)
14. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985;12:71-74. (Pubitemid 16002737)
15. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2013 DOI:10.1002/mds.25692.
16. Chipkin RE, Iorio LC, Coffin VL, et al. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 1988;247: 1093-1102. (Pubitemid 19022121)
17. McQuade RD, Duffy RA, Coffin VL, et al. In vivo binding of SCH 39166: a D-1 selective antagonist. J Pharmacol Exp Ther 1991;257:42-49.
18. McQuade RD, Duffy RA, Anderson CC, et al. [3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses. J Neurochem 1991;57:2001-2010. (Pubitemid 21922851)
19. Robertson MM, Banerjee S, Kurlan R, et al. The Tourette syndrome diagnostic confidence index: development and clinical associations. Neurology 1999;53:2108-2112.
20. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573. (Pubitemid 19196295)
21. Guy W. Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No ADM 76 1976;338:218-222.
22. Adler L, Kessler R, Spencer T. Adult ADHD Self-Report Scale (ASRS) Symptom Checklist. New York, NY: World Health Organization; 2003.
23. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-1016. (Pubitemid 19278230)
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Woods DW, Piacentini J, Himle MB, et al. Premonitory Urge for Tics Scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with tic disorders. J Dev Behav Pediatr 2005;26:397-403. (Pubitemid 44384144)
26. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.
27. Lidow MS, Goldman-Rakic PS, Rakic P, et al. Autoradiographic comparison of D1-specific binding of [3H]SCH39166 and [3H] SCH23390 in the primate cerebral cortex. Brain Res 1990;537:349-354.
28. Tice MA, Hashemi T, Taylor LA, et al. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem Behav 1994;49:567-571. (Pubitemid 24335637)
29. Hall H, Halldin C, Sedvall G. Binding of [3H]SCH 39166 to human post mortem brain tissue. Pharmacol Toxicol 1993;72:152-158. (Pubitemid 23122959)
30. Karlsson P, Sedvall G, Halldin C, et al. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. Psychopharmacology (Berl) 1995;121:300-308.
31. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950. (Pubitemid 26225470)
32. Ralph RJ, Caine SB. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 2005;312:733-741. (Pubitemid 40189573)
33. Nunes EJ, Randall PA, Santerre JL, et al. Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 2010;170:268-280.
34. Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005;20:714-718. (Pubitemid 41056938)
35. Smith-Hicks CL, Bridges DD, Paynter NP, et al. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007;22:1764-1770. (Pubitemid 47597600)
36. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996;57:29-31. (Pubitemid 26030525)
37. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;62:50-56. (Pubitemid 32154319)
38. Cubo E, Gonzalez M, Singer H, et al. Impact of placebo assignment in clinical trials of tic disorders. Mov Disord 2013;28:1288-1292.
39. Scahill L, Erenberg G, Berlin CMJr, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006;3:192-206. (Pubitemid 44061705)
40. Gilbert DL, Buncher CR. Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette's syndrome: a model for studies of multiple neuropsychiatric diagnoses. J Neuropsychiatry Clin Neurosci 2005;17:324-332. (Pubitemid 46179294)
41. Astrup A, Greenway FL, Ling W, et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) 2007;15:1717-1731. (Pubitemid 47264951)
42. Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 2001;62:290-294. (Pubitemid 32428769)
43. Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002;22:31-39. (Pubitemid 34101290)
44. Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Mov Disord 2000;15:1194-1198.
45. Gilbert DL, Dure L, Sethuraman G, et al. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003;60:606-611. (Pubitemid 36246077)
46. Kurlan R, Crespi G, Coffey B, et al. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Mov Disord 2012;27:775-778.
47. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 2011;21:600-620.
48. Wonodi I, Reeves G, Carmichael D, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord 2007;22:1777-1782. (Pubitemid 47597602)